IL231957A0 - New immune system modulators based on imidazole quinoline - Google Patents

New immune system modulators based on imidazole quinoline

Info

Publication number
IL231957A0
IL231957A0 IL231957A IL23195714A IL231957A0 IL 231957 A0 IL231957 A0 IL 231957A0 IL 231957 A IL231957 A IL 231957A IL 23195714 A IL23195714 A IL 23195714A IL 231957 A0 IL231957 A0 IL 231957A0
Authority
IL
Israel
Prior art keywords
immune system
based immune
imidazole quinoline
novel imidazole
system modulators
Prior art date
Application number
IL231957A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janus Biotherapeutics Inc
Lipford Grayson B
Zepp Charles M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janus Biotherapeutics Inc, Lipford Grayson B, Zepp Charles M filed Critical Janus Biotherapeutics Inc
Publication of IL231957A0 publication Critical patent/IL231957A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL231957A 2011-10-04 2014-04-06 New immune system modulators based on imidazole quinoline IL231957A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161543082P 2011-10-04 2011-10-04
PCT/US2012/058566 WO2013052550A2 (en) 2011-10-04 2012-10-03 Novel imidazole quinoline-based immune system modulators

Publications (1)

Publication Number Publication Date
IL231957A0 true IL231957A0 (en) 2014-05-28

Family

ID=48044383

Family Applications (1)

Application Number Title Priority Date Filing Date
IL231957A IL231957A0 (en) 2011-10-04 2014-04-06 New immune system modulators based on imidazole quinoline

Country Status (8)

Country Link
US (1) US9873694B2 (OSRAM)
EP (1) EP2763677B1 (OSRAM)
JP (1) JP2014528449A (OSRAM)
AU (1) AU2012318694B2 (OSRAM)
CA (1) CA2850932A1 (OSRAM)
IL (1) IL231957A0 (OSRAM)
IN (1) IN2014KN00948A (OSRAM)
WO (1) WO2013052550A2 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
EA038972B1 (ru) 2016-07-30 2021-11-16 Бристол-Маерс Сквибб Компани Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9
WO2018049089A1 (en) 2016-09-09 2018-03-15 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
EP3661934B1 (en) 2017-08-04 2022-06-01 Bristol-Myers Squibb Company [1,2,4]triazolo[4,3-a]pyridinyl substituted indole compounds
JP7104775B2 (ja) 2017-08-04 2022-07-21 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ７／８／９の阻害剤として有用な置換インドール化合物
CN111448190B (zh) 2017-11-14 2023-09-26 百时美施贵宝公司 取代的吲哚化合物
CN111527080B (zh) 2017-12-15 2023-09-22 百时美施贵宝公司 取代的吲哚醚化合物
LT3728252T (lt) 2017-12-18 2023-10-25 Bristol-Myers Squibb Company 4-azaindolo junginiai
EA202091483A1 (ru) 2017-12-19 2020-10-28 Бристол-Маерс Сквибб Компани Амидзамещенные индольные соединения, пригодные в качестве ингибиторов tlr
WO2019126113A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Substituted indole compounds useful as tlr inhibitors
CA3085761A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Triazole n-linked carbamoylcyclohexyl acids as lpa antagonists
CA3086431A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Amino indole compounds useful as tlr inhibitors
CN111511744B (zh) 2017-12-20 2023-09-22 百时美施贵宝公司 二氮杂吲哚化合物
MX2020005622A (es) 2017-12-20 2020-08-20 Bristol Myers Squibb Co Compuestos de indol sustituidos con arilo y heteroarilo.
WO2020086505A1 (en) 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole dimer compounds
WO2020086503A1 (en) 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole and indazole compounds
CN113811299A (zh) * 2019-03-15 2021-12-17 博笛生物科技有限公司 用于治疗癌症的免疫调控性组合物和方法
KR20220006571A (ko) 2019-05-09 2022-01-17 브리스톨-마이어스 스큅 컴퍼니 치환된 벤즈이미다졸론 화합물
CN114761404B (zh) 2019-10-01 2025-02-21 百时美施贵宝公司 经取代的双环杂芳基化合物
KR20220079587A (ko) 2019-10-04 2022-06-13 브리스톨-마이어스 스큅 컴퍼니 치환된 카르바졸 화합물
US11530218B2 (en) 2020-01-20 2022-12-20 Incyte Corporation Spiro compounds as inhibitors of KRAS
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
WO2022204112A1 (en) 2021-03-22 2022-09-29 Incyte Corporation Imidazole and triazole kras inhibitors
WO2022221642A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Thienopyrrole compounds
PE20241127A1 (es) 2021-07-07 2024-05-24 Incyte Corp Compuestos triciclicos como inhibidores de kras
EP4396187A1 (en) 2021-08-31 2024-07-10 Incyte Corporation Naphthyridine compounds as inhibitors of kras
TW202440078A (zh) 2021-09-10 2024-10-16 美商基利科學股份有限公司 噻吩并吡咯化合物
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
EP4408536A1 (en) 2021-10-01 2024-08-07 Incyte Corporation Pyrazoloquinoline kras inhibitors
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1271477A (en) * 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ES2366201T3 (es) 1994-07-15 2011-10-18 University Of Iowa Research Foundation Oligonucleótidos inmunmoduladores.
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
AR006928A1 (es) 1996-05-01 1999-09-29 Pioneer Hi Bred Int Una molecula de adn aislada que codifica una proteina fluorescente verde como marcador rastreable para la transformacion de plantas, un metodo para laproduccion de plantas transgenicas, un vector de expresion, una planta transgenica y celulas de dichas plantas.
JP2001513776A (ja) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＬＰＳ関連障害の処置における非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
EP1988166A1 (en) 1997-05-07 2008-11-05 Schering Corporation Human Toll-like receptor proteins, related reagents and methods
WO1998052581A1 (en) 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
AU3884199A (en) 1998-05-06 1999-11-23 Ottawa Health Research Institute Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
DE60036918D1 (de) 1999-01-22 2007-12-13 Elan Pharm Inc Verbindungen die die vla-4 vermittelte adhäsion von leukozyten inhibieren
MXPA02003059A (es) 1999-09-27 2002-09-30 Univ Iowa Res Found Metodos relacionados con interferon inducido por acido nucleico inmunoestabilizador.
JP2003533996A (ja) 2000-05-25 2003-11-18 シェーリング コーポレイション ヒトレセプタータンパク質、関連試薬および方法
DE60229422D1 (de) 2001-08-17 2008-11-27 Coley Pharm Gmbh Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
WO2005016235A2 (en) * 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
KR20060016817A (ko) * 2003-06-20 2006-02-22 콜리 파마슈티칼 게엠베하 소분자 톨-유사 수용체 (ｔｌｒ) 길항제
US8158794B2 (en) 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
CA2628131C (en) * 2005-11-04 2012-03-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
WO2007109810A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
US8027888B2 (en) * 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
US7943771B2 (en) * 2007-01-24 2011-05-17 Chemagis Ltd. Imiquimod production process
AU2007345952C1 (en) * 2007-01-31 2017-06-08 Chongxi Yu Positively charged water-soluble prodrugs of 1H-imidazo[4, 5-c]quinolin-4-amines and related compounds with very high skin penetration rates
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
TW201024297A (en) * 2008-09-10 2010-07-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
JP2013512859A (ja) * 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
US8728486B2 (en) * 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds

Also Published As

Publication number Publication date
WO2013052550A3 (en) 2014-05-15
EP2763677B1 (en) 2020-02-26
EP2763677A4 (en) 2015-05-20
AU2012318694B2 (en) 2016-12-22
JP2014528449A (ja) 2014-10-27
US20140242121A1 (en) 2014-08-28
WO2013052550A2 (en) 2013-04-11
IN2014KN00948A (OSRAM) 2015-08-21
CA2850932A1 (en) 2013-04-11
US9873694B2 (en) 2018-01-23
EP2763677A2 (en) 2014-08-13
AU2012318694A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
IL231957A0 (en) New immune system modulators based on imidazole quinoline
IL229541A0 (en) New immune system modulators
SG11201400645TA (en) Communication system
GB201112752D0 (en) Communication system
GB201116924D0 (en) Communication system
ZA201400611B (en) Shelf-monitoring system
EP2720442A4 (en) COMMUNICATION SYSTEM
GB201102883D0 (en) Communication system
GB201113943D0 (en) Communication system
GB201119207D0 (en) Communication system
GB201113942D0 (en) Communication system
GB201109100D0 (en) Transmission system
EP2719500A4 (en) PART PROCESSING SYSTEM
PL2785385T3 (pl) Sprzęt gospodarstwa domowego z systemem dezodoryzującym
GB2491044B (en) Ablutionary system
GB201120956D0 (en) Communication system
GB201204700D0 (en) Communication system
ZA201401657B (en) Pimping system
GB2495002B (en) Connection system
GB201120963D0 (en) Communication system
GB201113939D0 (en) Communication system
EP2757828A4 (en) COMMUNICATION SYSTEM
PL2741811T3 (pl) Układ do leczenia objawów
PL2872583T3 (pl) Układ adhezyjny
LT2731976T (lt) Klijų kompozicija